Priorix Vaccine Description
GlaxoSmithKline's Priorix vaccine is a lyophilized mixed preparation of the attenuated Schwarz measles, RIT 4385 mumps (derived from Jeryl Lynn strain), and Wistar RA 27/3 rubella strains of viruses.
The measles and mumps components of the vaccine are produced in chick embryo cell culture and may contain traces of egg protein.
Priorix was first registered in Germany in 1997 and is currently licensed outside the USA in over 100 countries, including Canada, the UK, and New Zealand. It is recommended for use in individuals aged ≥9 months, according to a 1- or 2-dose schedule, depending on the country.
GSK is a global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information, please GSK.
Priorix Vaccine Indication
Priorix is indicated to protect against measles, mumps, and rubella. It works by helping the body to make its own antibodies that protect your child against these diseases.
There are limited data on the use of PRIORIX in immunocompromised subjects; therefore, vaccination should be considered with caution and only when, in the opinion of the physician, the benefits outweigh the risks (e.g., asymptomatic HIV subjects).
Priorix Vaccine and Pregnant Women
Pregnant women must not be vaccinated with PRIORIX, says GSA. However, fetal damage has not been documented when measles, mumps, or rubella vaccines have been given to pregnant women. Therefore, inadvertent vaccination of unknowingly pregnant women with measles, mumps, and rubella-containing vaccines should not be a reason for termination of pregnancy. Nevertheless, women of child-bearing potential should be advised to avoid pregnancy for one month following vaccination.
Furthermore, there are no human data regarding use in breastfeeding women. Nursing mothers may be vaccinated where, in the judgment of the health professional, the benefit outweighs the risk.
Priorix Vaccine Dosage
Priorix is administered as a subcutaneous or Intramuscular injection in the deltoid region or the anterolateral area of the thigh. A single 0.5 mL dose of the reconstituted vaccine is recommended. A second dose of MMR is recommended at least 1 month after the first dose for better measles protection.
There is no difference between the first and second vaccine doses concerning the frequency category for the adverse reactions, except for pain at the injection site, which was "Common" after the first vaccine dose and "Very common" after the second vaccine dose.
PRIORIX-TETRA is a sterile lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain), the Wistar RA 27/3 rubella virus strain, and the OKA strain of the varicella-zoster virus. Each virus strain is separately produced in either chick embryo cells (mumps and measles) or MRC5 human diploid cells (rubella and varicella).
Although PRIORIX-TETRA contains live viruses, they are too weak to cause severe disease in healthy people. Occasionally, some spots, blisters, and fever may appear in the first two weeks after vaccination.
Priorix Vaccine News
September 14, 2021 - Virginia Health Officials report 5 measles cases in travelers from Afghanistan. Health departments are working together to identify people who may have been exposed at Dulles International Airport as well as Fort Pickett.
September 13, 2021 - Six measles cases were reported by the US CDC in areas around the United States.
August 2, 2021 - GSK announced it has submitted a Biologics License Application (BLA) to the US FDA for PRIORIX and is seeking approval for active immunization against infection by measles, mumps, and rubella.
March 24, 2021 - Vaccine manufacturers across the globe have been focusing on partnering with organizations such as WHO, UNICEF, and GAVI Alliance to improve their vaccination programs to reach the maximum population to offer vaccines. Despite several governmental initiatives, measles is a leading cause of death among young children.
April 30, 2020 - Study: Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as the First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. Conclusions: If licensed, the MMR-RIT could provide a valid option for preventing measles, mumps, and rubella in children in the United States and would reduce the potential risks of a vaccine shortage.
January 12, 2020 - A study published in the Pediatric Infectious Disease Society concluded saying, ‘if licensed, the Priorix / MMR-RIT vaccine could provide a valid option for the prevention of measles, mumps, and rubella in children, 12-to 15-months-old in the USA.
March 22, 2019 - A phase 3 study published in the Journal of the Pediatric Infectious Diseases Society found that GlaxoSmithKline’s MMR vaccine was safe and effective in healthy children.
Priorix Vaccine Clinical Trials
GSK continues to test the safety and efficacy of Priorix in clinical trials.